INGELHEIM  Germany--(BUSINESS WIRE)-- Boehringer Ingelheim today announced that it has acquired all shares of ViraTherapeutics  a biopharmaceutical company specializing in the development of oncolytic viral therapies ViraTherapeutics developed the lead candidate VSV-GP (Vesicular Stomatitis Virus (VSV) with modified glycoprotein (GP))  which is being investigated alone and in combination with other therapies